SecSonar.com

Alterity Therapeutics Limited (ATHE)

Alterity Therapeutics Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Alterity Therapeutics Limited (ATHE) is a Biotechnology company based in AU with a market capitalization of $36.5M. Revenue grew 35.3% year-over-year and free cash flow was negative at -$11.5M. This page tracks ATHE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

AU · 10 employees · IPO Sep 29, 2003

Valuation

Valuation & price

$4.17 · as of May 26, 2026 · -36.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.55$4.79$3.02Jul 25Dec 25Jul 26Jul 7, 25$3.87Jul 9, 25$3.91Jul 11, 25$4.59Jul 15, 25$4.47Jul 17, 25$4.61Jul 21, 25$4.90Jul 23, 25$4.99Jul 25, 25$6.55Jul 29, 25$5.34Jul 31, 25$5.06Aug 4, 25$5.21Aug 6, 25$5.15Aug 11, 25$5.32Aug 13, 25$5.14Aug 15, 25$5.25Aug 19, 25$4.95Aug 21, 25$5.10Aug 25, 25$5.10Aug 27, 25$5.00Aug 29, 25$4.94Sep 3, 25$5.07Sep 5, 25$5.07Sep 9, 25$5.02Sep 11, 25$4.94Sep 16, 25$4.45Sep 18, 25$4.38Sep 22, 25$4.43Sep 24, 25$4.39Sep 26, 25$3.95Sep 30, 25$3.76Oct 2, 25$4.19Oct 6, 25$4.33Oct 8, 25$4.31Oct 10, 25$4.29Oct 14, 25$4.73Oct 16, 25$4.83Oct 21, 25$4.76Oct 23, 25$4.60Oct 27, 25$4.51Oct 29, 25$4.70Oct 31, 25$4.21Nov 4, 25$3.73Nov 6, 25$3.50Nov 10, 25$3.75Nov 12, 25$3.79Nov 14, 25$3.84Nov 18, 25$3.60Nov 20, 25$3.52Nov 25, 25$3.51Nov 28, 25$3.60Dec 2, 25$3.34Dec 4, 25$3.43Dec 8, 25$3.29Dec 10, 25$3.35Dec 12, 25$3.29Dec 16, 25$3.07Dec 18, 25$3.03Dec 22, 25$3.15Dec 24, 25$3.10Dec 29, 25$3.02Jan 2, 26$3.16Jan 6, 26$3.21Jan 8, 26$3.33Jan 12, 26$3.52Jan 14, 26$3.32Jan 16, 26$3.45Jan 21, 26$3.25Jan 23, 26$3.55Jan 27, 26$3.51Jan 29, 26$3.26Feb 2, 26$3.11Feb 4, 26$3.14Feb 9, 26$3.57Feb 11, 26$3.53Feb 13, 26$3.49Feb 18, 26$3.41Feb 20, 26$3.30Feb 24, 26$3.33Feb 26, 26$3.53Mar 2, 26$3.45Mar 4, 26$3.40Mar 6, 26$3.43Mar 10, 26$3.62Mar 12, 26$3.55Mar 17, 26$3.34Mar 19, 26$3.45Mar 23, 26$3.30Mar 25, 26$3.41Mar 27, 26$3.16Mar 31, 26$3.48Apr 2, 26$3.56Apr 7, 26$3.76Apr 9, 26$3.85Apr 13, 26$3.66Apr 15, 26$3.73Apr 17, 26$4.47Apr 22, 26$4.54Apr 24, 26$4.41Apr 28, 26$4.58Apr 30, 26$4.54May 4, 26$4.52May 6, 26$4.52May 8, 26$4.66May 12, 26$4.83May 14, 26$4.67May 18, 26$4.34May 20, 26$4.27May 22, 26$4.14May 28, 26$4.08Jun 1, 26$4.02Jun 3, 26$4.01Jun 5, 26$3.90Jun 9, 26$4.29Jun 11, 26$4.11Jun 15, 26$4.41Jun 17, 26$5.14Jun 22, 26$4.93Jun 24, 26$5.07Jun 26, 26$4.82Jul 2, 26$5.43
$2.9252-week range$6.55
Loading valuation history…

Fundamentals

Key fundamentals

$36.5M

Market cap

35.3%

Revenue growth (YoY)

97.7%

Gross margin

-$11.5M

Free cash flow (USD)

-$40.5M

Net debt

Net cash position

75.3%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$142.7KFY 2017$132.4KFY 2018$201.2KFY 2019$108.5KFY 2020$0.00FY 2021$4.3MFY 2022$5.1MFY 2023$3.9MFY 2024$4.0MFY 2025$5.4M
$142.7K$5.4M

Free cash flow by year

2016 → 2025

FY 2016$-7.4MFY 2017$-5.9MFY 2018$-6.3MFY 2019$-14.0MFY 2020$-9.4MFY 2021$-17.3MFY 2022$-12.4MFY 2023$-20.0MFY 2024$-12.6MFY 2025$-11.5M
-$7.4M-$11.5M

Gross margin by year

2021 → 2025

FY 202191.7%FY 202292.9%FY 202392.7%FY 202494.7%FY 202597.7%
91.7%97.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 29, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingApplication for QuotationJul 1, 2026Filing
  • 6-K filingChange in Substantial HoldingJun 30, 2026Filing
  • 6-K filingChange of Director's Interest NoticeJun 17, 2026Filing
  • 6-K filingCorporate PresentationJun 16, 2026Filing
  • 6-K filingNotification regarding unquoted securitiesJun 15, 2026Filing
  • 6-K filingNotification of Cessation of SecuritiesJun 15, 2026Filing
  • 6-K filingCapital Consolidation CompletedJun 12, 2026Filing
  • 6-K filingFDA Alignment on Phase 3 ProgramJun 9, 2026Filing
  • 6-K filingShare ConsolidationJun 4, 2026Filing
  • 6-K filingChange of Registered Office AddressJun 3, 2026Filing

Questions

Frequently asked questions

What is Alterity Therapeutics Limited's market cap?

Alterity Therapeutics Limited (ATHE) has a market capitalization of $36.5M.

What is ATHE's P/E ratio?

A meaningful P/E ratio is not available for ATHE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying ATHE stock?

SEC Form 4 filings show no open-market insider buys at Alterity Therapeutics Limited in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

INMB

INmune Bio, Inc.

$36.3M

BTAI

BioXcel Therapeutics, Inc.

$37.1M

VERU

Veru Inc.

$37.4M

ALGS

Aligos Therapeutics, Inc.

$35.5M

RNXT

RenovoRx, Inc.

$35M

SABS

SAB Biotherapeutics, Inc.

$34.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.